摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-三氟甲氧基苯基)乙醇 | 642444-30-2

中文名称
2-(3-三氟甲氧基苯基)乙醇
中文别名
2-(3-(三氟甲氧基)苯基)乙醇
英文名称
2-[3-(trifluoromethoxy)phenyl]ethanol
英文别名
2-(3-(Trifluoromethoxy)phenyl)ethanol
2-(3-三氟甲氧基苯基)乙醇化学式
CAS
642444-30-2
化学式
C9H9F3O2
mdl
——
分子量
206.164
InChiKey
YPZUGJLCXIAZNI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    217.5±35.0 °C(Predicted)
  • 密度:
    1.287±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

反应信息

  • 作为反应物:
    描述:
    2-(3-三氟甲氧基苯基)乙醇硫酰氟potassium carbonate 作用下, 以 二甲基亚砜 为溶剂, 反应 2.0h, 生成 C9H6F4O4S
    参考文献:
    名称:
    Transition-metal-free regioselective construction of 1,5-diaryl-1,2,3-triazoles through dehydrative cycloaddition of alcohols with aryl azides mediated by SO2F2
    摘要:
    开发了一种新颖、简单且实用的方法,用于高效、经济、具有区域选择性的合成高价值的1,5-二芳基-1,2,3-三唑。
    DOI:
    10.1039/c8cc09693g
  • 作为产物:
    描述:
    环氧乙烷3-三氟甲氧基溴苯正丁基锂 作用下, 以 乙醚正己烷 为溶剂, 反应 0.75h, 以78%的产率得到2-(3-三氟甲氧基苯基)乙醇
    参考文献:
    名称:
    2-、3- 和 4-(三氟甲氧基)苯基锂:多功能中间体,可提供各种新型有机氟化合物
    摘要:
    用仲丁基锂和亲电试剂连续处理(三氟甲氧基)苯,可得到以前无法获得的邻位取代衍生物。在一般优良的产量。2-(三氟甲氧基)苯基锂是关键中间体。通过卤素-金属与丁基锂或叔丁基锂的相互转化,可以很容易地从相应的 3- 和 4- 溴前体生成 3- 和 4- 异构体。用 11 种不同的亲电子试剂(B(OH)2、OH、Br、I、CH3、EtOH、CHO、COCOOEt、COCH2COOEt、COOH、CN)捕获 2-、3- 和 4-(三氟甲氧基)苯基锂后,得到预期产物通常以高产率(高达 95%)形成。只有尝试亲核添加。2-(三氟甲氧基)苯基锂转化为环氧乙烷未成功。这种失败暂时归因于氟-锂相互作用导致的亲核性降低。构象受限的类似物 - 即 2,2-difluoro-1,3-benzodioxol-4-phenyllithium 及其 5-fluoro- 和 5-bromo-取代的同类物 - 确实与环氧乙烷顺利反应,以普通产率提供加合物。[在
    DOI:
    10.1002/1099-0690(200102)2001:4<691::aid-ejoc691>3.0.co;2-a
点击查看最新优质反应信息

文献信息

  • Novel pyridopyprimidinone derivatives which are HM74A agonists
    申请人:Conte Aurelia
    公开号:US20070275987A1
    公开(公告)日:2007-11-29
    The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R 1 to R 8 , X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.
    这项发明涉及式(I)的新型吡啶吡嘧啶酮衍生物:其中R1至R8、X、Y、m和n如描述和索赔中所定义。本发明的化合物是HM74A激动剂,与烟酸相比具有改进的性能,并可用于治疗和/或预防与HM74A相关的疾病,如脂质代谢异常、动脉粥样硬化、糖尿病、代谢综合征和其他与HM74A相关的疾病。
  • [EN] ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS CYCLIQUES ACYLAMINO-SUBSTITUÉS DE L'ACIDE CARBOXYLIQUE ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
    申请人:SANOFI AVENTIS
    公开号:WO2011053948A1
    公开(公告)日:2011-05-05
    The present invention relates to compounds of the formula (I) wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.
    本发明涉及式(I)的化合物,其中A、Y、Z、R20至R22和R50具有索引中指示的含义,这些化合物是有价值的药用活性化合物。具体来说,它们是内皮分化基因受体2(Edg-2,EDG2)的抑制剂,该受体被溶血磷脂酸(LPA)激活,也被称为LPA1受体,对于治疗动脉粥样硬化、心肌梗死和心力衰竭等疾病是有用的。此外,本发明还涉及制备式(I)化合物的方法、它们的用途以及包含它们的药物组合物。
  • [EN] 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS<br/>[FR] COMPOSES 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE POUR LE TRAITEMENT DE LA TUBERCULOSE
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2005042542A1
    公开(公告)日:2005-05-12
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1)in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and -(CH2)nR2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30)and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.
    本发明提供了一种由以下一般式表示的2,3-二氢-6-硝基咪唑[2,1-b]噁唑化合物:(1)在上述式(1)中,R1代表氢原子或C1-C6烷基,n代表0至6的整数,R1和-(CH2)nR2可以与下面的式(30)一起形成一个螺环,与相邻的碳原子一起(在下面的式中,RRR代表可能在哌啶环上具有取代基的哌啶基),(30)和R2代表苯并噻唑氧基、喹啉氧基、吡啶氧基或类似物。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型耐酸细菌具有出色的杀菌作用。
  • 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
    申请人:Tsubouchi Hidetsugu
    公开号:US20060094767A1
    公开(公告)日:2006-05-04
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.
    本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物,其通式如下:其中,R1代表氢原子或C1-C6烷基,n代表0到6的整数,R2代表—OR3或类似的基团,R3代表氢原子、C1-C6烷基或类似的基团,或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环,其通式为(H):其中,R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
  • 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis
    申请人:Tsubouchi Hidetsugu
    公开号:US20080119478A1
    公开(公告)日:2008-05-22
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and —(CH2) n R2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30) and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.
    本发明提供了一种由下述通式(1)表示的2,3-二氢-6-硝基咪唑[2,1-b]噁唑化合物: 在上述式(1)中,R1代表氢原子或C1-C6烷基,n代表0到6的整数,R1和—(CH2)nR2可以与相邻的碳原子形成如下式(30)所示的螺环,其中,在下式中,RRR代表可能在哌啶环上具有取代基的哌啶基: (30)且R2代表苯并噻唑氧基、喹啉氧基、吡啶氧基或类似基团。该化合物对结核分枝杆菌、多重耐药结核分枝杆菌和非典型酸杆菌具有优异的杀菌作用。
查看更多